Home » ProciseDx Gets CE Mark for Additional Point-of-Care Drug Monitoring Tests
ProciseDx Gets CE Mark for Additional Point-of-Care Drug Monitoring Tests
ProciseDx has earned a CE mark for two new point-of-care tests for the immunosuppressive drugs infliximab and adalimumab for use on its ProciseDx system.
The tests gauge the levels of the drugs present in fingerprick-blood samples, returning results in less than five minutes.
The test data will “allow physicians to make timely dosing decisions and thereby improve drug efficacy,” said ProciseDx CEO Larry Mimms.
Upcoming Events
-
07May
-
14May
-
30May